EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study

Sebastiaan N Siegerink iD, Steven C Kuijper, Tom van den Ende iD, Rob H A Verhoeven iD, Sjoerd G Elias, Nadia Haj Mohammad, Marije Slingerland iD, Sarah Derks, Hanneke W M van Laarhoven iD

Therapeutic Advances in Medical Oncology · 2026-06 · 18

DOI: 10.1177/17588359261442616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 03.06.2026. Verfasst von Sebastiaan N Siegerink und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam UMC, Office 8D-XXX, PO Box 22660, Amsterdam 1100DD, The Netherlands. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival.

Objectives

We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms of overall survival for patients with gastroesophageal adenocarcinoma who have disease progression on first-line treatment.

Design

We performed a target trial emulation with a propensity-scored inverse probability weighting approach to resemble a randomized controlled trial.

Methods

Observational data was retrieved from the Netherlands Cancer Registry between 2015 and 2018, with a maximum follow-up until 2022. Patients were included if they received a fluoropyrimidine with oxaliplatin in first-line and as subsequent treatment OXR or PR. There was at least 6 months between planned discontinuation of oxaliplatin and disease progression.

Results

We included 129 patients in our model and the weighted cohort was well balanced between the two groups. No statistically significant difference in overall survival was observed between treatment groups (HR: 0.76, 95% CI: 0.3–1.5; p = 0.36). Median overall survival was 9.2 months (95% CI: 3.7–25.1) for OXR and 7.9 months (95% CI: 2.8–11.5) for PR ( p = 0.38). Exploratory subgroup analysis did not reach statistical significance. Patients in the OXR-group more often received one or more additional treatment lines, including second-line PR, than patients in the PR group, 47.7% versus 23.3%, respectively.

Conclusion

OXR following prolonged response to first-line treatment was associated with similar overall survival compared with PR. In the absence of a demonstrated survival benefit for either treatment, these results propose oxaliplatin reintroduction as a potential option in selected patients.

Schlagwörter

Stichwörter der Autor:innen

beyond first-line treatmentesophagogastric canceroxaliplatin reintroductionpaclitaxel-ramucirumabtarget trial emulation

Autor:innen und Institutionen

  • Department of Medical Oncology, Amsterdam UMC, Office 8D-XXX, PO Box 22660, Amsterdam 1100DD, The Netherlands.
  • Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
  • Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Sebastiaan N Siegerink, Tom van den Ende, Rob H A Verhoeven, Marije Slingerland, Hanneke W M van Laarhoven

Zitieren

APA

Siegerink, S. N., Kuijper, S. C., van den Ende, T., Verhoeven, R. H. A., Elias, S. G., Mohammad, N. H., Slingerland, M., Derks, S., & van Laarhoven, H. W. M. (2026). Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261442616

Vancouver

Siegerink SN, Kuijper SC, van den Ende T, Verhoeven RHA, Elias SG, Mohammad NH, et al. Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261442616

BibTeX
@article{Siegerink2026,
  author = {Siegerink, Sebastiaan N and Kuijper, Steven C and van den Ende, Tom and Verhoeven, Rob H A and Elias, Sjoerd G and Mohammad, Nadia Haj and Slingerland, Marije and Derks, Sarah and van Laarhoven, Hanneke W M},
  title = {Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261442616}
}
Kostenlos starten →